| Product | Indication | Dosage form | Strength |
|---|---|---|---|
| Depression | Tablets | 10 and 20 mg | |
| Amitriptyline | Major depressive disorders and anxiety | Film-coated tablets | 10, 25, 50 and 75 mg |
| Aripiprazole | Schizophrenia, bipolar disorder | Tablets | 5, 10, 15, 20 and 30 mg |
| Azithromycin | Macrolide antibacterial | Film-coated tablets | 500 mg |
| Azithromycin | Macrolide antibacterial | Powder for oral suspension | 200 mg/5 ml |
| Baclofen | Spasticity | Injection | 10 mg/5 ml and 10 mg/20 ml |
| Baclofen | Spasticity | Tablets | 25 mg |
| Buprenorphine | Opioid dependence | 0,4/ 1/ 2/ 4/ 6 & 8 mg sublingual films | |
| Carmellose - Artificial tears | Dry eye | Eye drops, solution | 2 mg (unit dose) |
| Ciprofloxacin otic | Otitis | Ear drops, solution (unit dose) | 1 mg |
| Clonazepam | Epilepsy | Oral drops, solution | 2.5 mg/ml |
| Clonazepam | Epilepsy | Tablets | 0.5 and 2 mg |
| Clopidogrel | Atherothrombosis | Film-coated tablets | 75 mg |
| Desloratadine | Allergy | Film-coated tablets | 5 mg |
| Dexketoprofen | Analgesic | Film-coated tablets | 12.5 and 25 mg |
| Duloxetine * | Major depressive disorders, neuropathic pain, anxiety | Gastro resistant hard capsules | 30, 60, 90 and 120 mg |
| Enalapril | Hypertension | Tablets | 5 and 20 mg |
| Enalapril + HCTZ | Hypertension | Tablets | 20/12.5 mg |
| Eslicarbazepine | Epilepsy | Tablets | 400 and 1200 mg |
| Eslicarbazepine acetate | Epilepsy | Film-coated tablets | 800 mg |
[*] Differentiated product
[**] Opioid
Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.
© Neuraxpharm / LESVI. All rights reserved.